Highlights and Quick Summary
- Ending Cash for the quarter ending September 30, 2022 was $-109 Million (a 249.73% increase compared to previous quarter)
- Year-over-year quarterly Ending Cash increased by 101.59%
- Annual Ending Cash for 2021 was $573 Million (a 223.56% increase from previous year)
- Annual Ending Cash for 2020 was $177 Million (a 250.15% increase from previous year)
- Annual Ending Cash for 2019 was $50.6 Million (a -65.83% decrease from previous year)
- Twelve month Ending Cash ending September 30, 2022 was $115 Million (a -81.56% decrease compared to previous quarter)
- Twelve month trailing Ending Cash decreased by -79.9% year-over-year
Trailing Ending Cash for the last four month:
| 30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
|---|---|---|---|
| $115 Million | $624 Million | $770 Million | $573 Million |
Visit stockrow.com/BEAM
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Ending Cash of Beam Therapeutics Inc.
Most recent Ending Cashof BEAM including historical data for past 10 years.Interactive Chart of Ending Cash of Beam Therapeutics Inc.
Beam Therapeutics Inc. Ending Cash for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | $-109.11 | $-31.2 | $309.57 | – |
| 2021 | $-54.12 | $400.01 | $114.77 | $112.08 | $572.74 |
| 2020 | $24.27 | $14.11 | $-0.75 | $139.38 | $177.01 |
| 2019 | $-0.54 | $-0.09 | $-106.45 | $157.63 | $50.55 |
| 2018 | $147.94 | – | – | – | $147.94 |
Business Profile of Beam Therapeutics Inc.
Sector: Healthcare
Industry: Biotechnology